Cargando…

OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups

BACKGROUND: Tumor-infiltrating immune cell compositions have been previously correlated to encouragement or inhibition of tumor growth. This association highlights immune-landscape profiling through non-invasive methods as a crucial step in approaches to treatment of patients with meningioma (MNG),...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrgott, Grayson, She, Ruicong, Sabedot, Thais, Wells, Michael, Asmaro, Karam, Malta, Tathiane, Mosella, Maritza, Nelson, Kevin, deCarvalho, Ana, Poisson, Laila, Mukherjee, Abir, Cazacu, Simona, Robin, Adam, Lee, Ian, Snyder, James, Walbert, Tobias, Rosenblum, Mark, Mikkelsen, Tom, Kalkanis, Steven, Rock, Jack, Noushmehr, Houtan, Castro, Ana Valeria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264924/
http://dx.doi.org/10.1093/noajnl/vdab070.056
_version_ 1783719665367777280
author Herrgott, Grayson
She, Ruicong
Sabedot, Thais
Wells, Michael
Asmaro, Karam
Malta, Tathiane
Mosella, Maritza
Nelson, Kevin
deCarvalho, Ana
Poisson, Laila
Mukherjee, Abir
Cazacu, Simona
Robin, Adam
Lee, Ian
Snyder, James
Walbert, Tobias
Rosenblum, Mark
Mikkelsen, Tom
Kalkanis, Steven
Rock, Jack
Noushmehr, Houtan
Castro, Ana Valeria
author_facet Herrgott, Grayson
She, Ruicong
Sabedot, Thais
Wells, Michael
Asmaro, Karam
Malta, Tathiane
Mosella, Maritza
Nelson, Kevin
deCarvalho, Ana
Poisson, Laila
Mukherjee, Abir
Cazacu, Simona
Robin, Adam
Lee, Ian
Snyder, James
Walbert, Tobias
Rosenblum, Mark
Mikkelsen, Tom
Kalkanis, Steven
Rock, Jack
Noushmehr, Houtan
Castro, Ana Valeria
author_sort Herrgott, Grayson
collection PubMed
description BACKGROUND: Tumor-infiltrating immune cell compositions have been previously correlated to encouragement or inhibition of tumor growth. This association highlights immune-landscape profiling through non-invasive methods as a crucial step in approaches to treatment of patients with meningioma (MNG), a prevalent primary intracranial tumor. Genome-wide DNA methylation patterns can aid in definition and assessment of cell compositions in liquid biopsy serum specimens, and allow for development of machine-learning models with predictive capabilities. METHODS: We profiled the cfDNA methylome (EPIC array) in liquid biopsy specimens from patients with MNG (n = 63) and nontumor controls (n = 6). We conducted both unsupervised epigenome-wide and supervised analyses of the meningioma methylome. Estimation of immune cell composition was conducted using Python-based methodology, where a reference methylome atlas of chosen cell types (B-cells, CD4- and CD8T-cells, neutrophils, natural killer cells, monocytes, cortical neuron, vascular endothelial cells, and healthy meninge) was used to deconvolute the MNG samples. Recurrence risk was estimated using an existing methylation-based Random-Forest classifier previously reported and validated, adapted to our serum-based cohort through employment of translatable meningioma subgroup-specific methylation markers (differentially methylated probes). RESULTS: We identified four distinct genome-wide methylation subgroups (k-clusters) of MNG which presented differential tumor micro-environments across all cell types investigated. Application of the DNA methylation-based Random-Forest classifier allowed for categorization of primary MNG serum samples into estimated recurrence-risk subgroups. Significantly contrasting micro-environments for the subgroups were observed across several cell-types, with those MNG more likely to recur displaying depletion in cell types reported to improve anti-tumoral response in many tumors (e.g. T-Cells). CONCLUSIONS: DNA methylation based deconvolution allowed for detection of contrasting tumor microenvironment compositions across MNG methylation subtypes and recurrence-risk estimation subgroups. These results suggest that microenvironment profiling can be informative of probable tumor behavior and prognostic outcomes, helping guide therapeutic approaches towards treatment of patients with MNG.
format Online
Article
Text
id pubmed-8264924
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-82649242021-07-08 OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups Herrgott, Grayson She, Ruicong Sabedot, Thais Wells, Michael Asmaro, Karam Malta, Tathiane Mosella, Maritza Nelson, Kevin deCarvalho, Ana Poisson, Laila Mukherjee, Abir Cazacu, Simona Robin, Adam Lee, Ian Snyder, James Walbert, Tobias Rosenblum, Mark Mikkelsen, Tom Kalkanis, Steven Rock, Jack Noushmehr, Houtan Castro, Ana Valeria Neurooncol Adv Supplement Abstracts BACKGROUND: Tumor-infiltrating immune cell compositions have been previously correlated to encouragement or inhibition of tumor growth. This association highlights immune-landscape profiling through non-invasive methods as a crucial step in approaches to treatment of patients with meningioma (MNG), a prevalent primary intracranial tumor. Genome-wide DNA methylation patterns can aid in definition and assessment of cell compositions in liquid biopsy serum specimens, and allow for development of machine-learning models with predictive capabilities. METHODS: We profiled the cfDNA methylome (EPIC array) in liquid biopsy specimens from patients with MNG (n = 63) and nontumor controls (n = 6). We conducted both unsupervised epigenome-wide and supervised analyses of the meningioma methylome. Estimation of immune cell composition was conducted using Python-based methodology, where a reference methylome atlas of chosen cell types (B-cells, CD4- and CD8T-cells, neutrophils, natural killer cells, monocytes, cortical neuron, vascular endothelial cells, and healthy meninge) was used to deconvolute the MNG samples. Recurrence risk was estimated using an existing methylation-based Random-Forest classifier previously reported and validated, adapted to our serum-based cohort through employment of translatable meningioma subgroup-specific methylation markers (differentially methylated probes). RESULTS: We identified four distinct genome-wide methylation subgroups (k-clusters) of MNG which presented differential tumor micro-environments across all cell types investigated. Application of the DNA methylation-based Random-Forest classifier allowed for categorization of primary MNG serum samples into estimated recurrence-risk subgroups. Significantly contrasting micro-environments for the subgroups were observed across several cell-types, with those MNG more likely to recur displaying depletion in cell types reported to improve anti-tumoral response in many tumors (e.g. T-Cells). CONCLUSIONS: DNA methylation based deconvolution allowed for detection of contrasting tumor microenvironment compositions across MNG methylation subtypes and recurrence-risk estimation subgroups. These results suggest that microenvironment profiling can be informative of probable tumor behavior and prognostic outcomes, helping guide therapeutic approaches towards treatment of patients with MNG. Oxford University Press 2021-07-05 /pmc/articles/PMC8264924/ http://dx.doi.org/10.1093/noajnl/vdab070.056 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Abstracts
Herrgott, Grayson
She, Ruicong
Sabedot, Thais
Wells, Michael
Asmaro, Karam
Malta, Tathiane
Mosella, Maritza
Nelson, Kevin
deCarvalho, Ana
Poisson, Laila
Mukherjee, Abir
Cazacu, Simona
Robin, Adam
Lee, Ian
Snyder, James
Walbert, Tobias
Rosenblum, Mark
Mikkelsen, Tom
Kalkanis, Steven
Rock, Jack
Noushmehr, Houtan
Castro, Ana Valeria
OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups
title OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups
title_full OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups
title_fullStr OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups
title_full_unstemmed OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups
title_short OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups
title_sort otme-5. meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264924/
http://dx.doi.org/10.1093/noajnl/vdab070.056
work_keys_str_mv AT herrgottgrayson otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT sheruicong otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT sabedotthais otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT wellsmichael otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT asmarokaram otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT maltatathiane otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT mosellamaritza otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT nelsonkevin otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT decarvalhoana otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT poissonlaila otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT mukherjeeabir otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT cazacusimona otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT robinadam otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT leeian otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT snyderjames otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT walberttobias otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT rosenblummark otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT mikkelsentom otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT kalkanissteven otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT rockjack otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT noushmehrhoutan otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups
AT castroanavaleria otme5meningiomaliquidbiopsyspecimensexhibitcontrastingimmunecelllandscapesacrossmethylationsubtypesandestimatedrecurrencerisksubgroups